Theravance Common Stock Shares Outstanding from 2010 to 2024
| TBPH Stock | USD 8.98 0.14 1.54% |
Common Stock Shares Outstanding | First Reported 2013-03-31 | Previous Quarter 49.4 M | Current Value 48.3 M | Quarterly Volatility 13.9 M |
Check Theravance Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theravance main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 2.2 M or Total Revenue of 56.6 M, as well as many exotic indicators such as Price To Sales Ratio of 10.28, Dividend Yield of 0.0 or PTB Ratio of 3.06. Theravance financial statements analysis is a perfect complement when working with Theravance Biopharma Valuation or Volatility modules.
Theravance | Common Stock Shares Outstanding |
Latest Theravance Biopharma's Common Stock Shares Outstanding Growth Pattern
Below is the plot of the Common Stock Shares Outstanding of Theravance Biopharma over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. Theravance Biopharma's Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theravance Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Shares Outstanding | 10 Years Trend |
|
Common Stock Shares Outstanding |
| Timeline |
Theravance Common Stock Shares Outstanding Regression Statistics
| Arithmetic Mean | 47,670,347 | |
| Geometric Mean | 45,584,267 | |
| Coefficient Of Variation | 30.64 | |
| Mean Deviation | 12,607,496 | |
| Median | 52,352,000 | |
| Standard Deviation | 14,607,799 | |
| Sample Variance | 213.4T | |
| Range | 41.8M | |
| R-Value | 0.86 | |
| Mean Square Error | 59.1T | |
| R-Squared | 0.74 | |
| Significance | 0.000036 | |
| Slope | 2,815,143 | |
| Total Sum of Squares | 2987.4T |
Theravance Common Stock Shares Outstanding History
About Theravance Biopharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Theravance Biopharma income statement, its balance sheet, and the statement of cash flows. Theravance Biopharma investors use historical funamental indicators, such as Theravance Biopharma's Common Stock Shares Outstanding, to determine how well the company is positioned to perform in the future. Although Theravance Biopharma investors may use each financial statement separately, they are all related. The changes in Theravance Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Theravance Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Theravance Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Theravance Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 55.3 M | 53.3 M |
Currently Active Assets on Macroaxis
When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:Check out the analysis of Theravance Biopharma Correlation against competitors. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 1.191 | Quarterly Revenue Growth 0.392 | Return On Assets (0.06) | Return On Equity (0.16) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.